Ibrutinib is a kinase inhibitor indicated for the treatment of various B-cell malignancies and chronic graft-versus-host disease (cGVHD).
1. Standard Dosage and Administration
1.1 For Adult Patients with CLL/SLL and WM
(1) 420 mg orally once daily until disease progression or unacceptable toxicity.
(2) May be used in combination with rituximab, obinutuzumab, or bendamustine.
1.2 For Pediatric Patients with cGVHD (Aged 12 Years and Older)
420 mg orally once daily.
1.3 For Pediatric Patients with cGVHD (Aged 1 to Less Than 12 Years)
240 mg/m² orally once daily based on body surface area, with a maximum dose not exceeding 420 mg.
1.4 Administration Instructions
(1) Swallow capsules/tablets whole with a full glass of water. Do not open, break, or chew capsules; do not cut, crush, or chew tablets.
(2) Take at approximately the same time each day.
2. Management of Missed Doses and Overdose
2.1 Missed Dose
(1) If a dose is missed, take it as soon as possible on the same day. Resume the regular dosing schedule the next day.
(2) Never take a double dose to make up for a missed one.
2.2 Overdose
There is no specific antidote for ibrutinib overdose. Close monitoring and supportive care are required.
3. Core Precautions During Treatment
3.1 Bleeding Risk
(1) Severe bleeding occurs in approximately 4.2% of patients; risk is higher with concomitant anticoagulant or antiplatelet therapy.
(2) Consider withholding treatment for 3–7 days before surgery based on procedure type and bleeding risk.
3.2 Infection Monitoring
(1) Grade 3 or higher infections occur in 21% of patients; be alert for opportunistic infections (e.g., PJP, PML).
(2) Seek immediate medical attention if fever develops.
3.3 Cardiac Events
(1) Atrial fibrillation (3.7%), heart failure (1.3%), and ventricular arrhythmias (0.2%) have been reported新疆维吾尔自治区药品监督管理局.
(2) Patients with cardiac risk factors face higher risk; monitor heart rate and symptoms regularly.
3.4 Blood Pressure Management
(1) Hypertension occurs in 19% of patients, with a median onset of 5.9 months.
(2) Monitor blood pressure regularly; initiate antihypertensive therapy if needed.
3.5 Hematologic Cytopenias
(1) Neutropenia (23%), thrombocytopenia (8%), and anemia (2.8%).
(2) Repeat complete blood count (CBC) monthly.
4. Healthy Lifestyle Recommendations for Patients
4.1 Dietary Considerations
Avoid grapefruit juice, grapefruit, or Seville oranges during treatment. These foods inhibit CYP3A and increase ibrutinib plasma concentrations.
4.2 Diarrhea Management
(1) Diarrhea occurs in approximately 43% of patients, commonly around 21 days after treatment initiation.
(2) Maintain adequate hydration to prevent dehydration. Inform your doctor promptly if diarrhea persists.
4.3 Sun Protection and Skin Care
(1) Second primary malignancies occur in 10% of patients, with non-melanoma skin cancer accounting for 6%.
(2) Practice strict sun protection and undergo regular skin examinations during treatment.
4.4 Contraception and Pregnancy
(1) Ibrutinib may cause fetal harm.
(2) Women of childbearing potential must use effective contraception during treatment and for 1 month after discontinuation.
(3) Breastfeeding is not recommended during treatment and for 1 week after the last dose.
4.5 Oral Care
(1) Stomatitis (mouth sores) is a common adverse reaction, especially in cGVHD patients.
(2) Maintain good oral hygiene; manage pain or ulcers promptly if they occur.
4.6 Regular Follow-Ups
Evaluate efficacy and adverse reactions every 1–2 months. Monitor liver/kidney function, electrocardiogram (ECG), blood pressure, and CBC to detect and manage potential issues early.
